- Not yet recruiting
NCT04864522: Phase 1: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma
Updated: May 25, 2022
MM BATs
NCT04864522: Phase 1: Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs)

Pilot Study of SLAMF7 BATs/CS-1 BATs in Relapsed/Refractory Multiple Myeloma (MM BATs)
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-SLAMF7 bispecific antibody armed activated T cells (SLAMF7 BATs/CS1 BATs) for patients with relapsed and/or refractory multiple myeloma. Patients receive 4 weekly doses and then 4 more doses every 2 weeks of SLAMF7 BATs by intravenous infusion. If patients have at least stable disease after these infusions, then they may receive additional infusions every 4 weeks up to a maximum of 21 infusions (including the initial 8 infusions).
Sponsor
University of Virginia
Location
United States, Virginia
ClinicalTrials.gov Identifier: NCT04864522
Official Title: Pilot Study of Anti-CD3 x Anti-SLAMF7 (Anti-CS-1) Bispecific Antibody Armed Activated T-Cells (SLAMF7 BATs/CS-1 BATs) in Relapsed/Refractory Multiple Myeloma
First Posted : April 29, 2021
Click here to see details on ClinicalTrials.gov
Drug: SLAMF7 BATs